Wedbush Securities Inc Verona Pharma PLC Transaction History

Wedbush Securities Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 08, 2021	SELL	$5.29 - $6.35 $95,405 - $114,522	-18,035 Closed	0 $0
Q2 2021 Jul 27, 2021	SELL	$5.72 - $9.09 $22,679 - $36,041	-3,965 Reduced 18.02%	18,035 $117,000
Q1 2021 Apr 26, 2021	BUY	$7.08 - $9.33 $70,800 - $93,300	10,000 Added 83.33%	22,000 $183,000
Q4 2020 Feb 16, 2021	SELL	$5.51 - $8.11 $172,463 - $253,842	-31,300 Reduced 72.29%	12,000 $84,000
Q3 2020 Oct 20, 2020	SELL	$4.45 - $10.2 $292,810 - $671,160	-65,800 Reduced 60.31%	43,300 $270,000
Q2 2020 Jul 16, 2020	BUY	$3.6 - $6.12 $137,340 - $233,478	38,150 Added 53.77%	109,100 $511,000
Q1 2020 Apr 17, 2020	SELL	$2.16 - $7.28 $21,924 - $73,892	-10,150 Reduced 12.52%	70,950 $292,000
Q4 2019 Jan 16, 2020	BUY	$3.7 - $6.58 $187,904 - $334,165	50,785 Added 167.52%	81,100 $466,000
Q3 2019 Oct 17, 2019	BUY	$4.03 - $5.44 $24,180 - $32,640	6,000 Added 24.68%	30,315 $139,000
Q2 2019 Aug 01, 2019	SELL	$5.1 - $6.91 $2,473 - $3,351	-485 Reduced 1.96%	24,315 $124,000
Q1 2019 Apr 17, 2019	BUY	$5.52 - $10.0 $58,898 - $106,700	10,670 Added 75.51%	24,800 $161,000
Q4 2018 Jan 31, 2019	BUY	$9.0 - $13.47 $127,170 - $190,331	14,130 New	14,130 $127,000

167

68.7M

704K

685K

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $2.84B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

Get notified when there are updates to the investment portfolio of Wedbush Securities Inc, based on Form 13F filings with the SEC.

Stay updated on Wedbush Securities Inc with notifications on news.